Hiroshi Kobayashi1, Tomotake Okuma2, Hiroyuki Oka3, Toshihide Hirai4, Takahiro Ohki2, Masachika Ikegami4, Ryoko Sawada4, Yusuke Shinoda4, Toru Akiyama5, Kenji Sato6, Satoshi Abe6, Hirotaka Kawano6, Takahiro Goto2, Sakae Tanaka4. 1. Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. hkobayashi-tky@umin.ac.jp. 2. Department of Musculoskeletal Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. 3. Department of Medical Research and Management for Musculoskeletal Pain, 22nd Century Medical and Research Center, Faculty of Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. 4. Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. 5. Department of Orthopaedic Surgery, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya-ku, Saitama-shi, Saitama, 330-8503, Japan. 6. Department of Orthopaedic Surgery, Faculty of Medicine, University of Teikyo, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8606, Japan.
Abstract
BACKGROUND: Pazopanib is a multi-tyrosine kinase inhibitor that is used to treat advanced soft-tissue sarcoma, and its efficacy has been confirmed in several clinical trials, although no clinically useful biomarkers have been identified. In other cancers, the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the lymphocyte-to-monocyte ratio (LMR) are associated with chemotherapy response and prognosis. Therefore, we aimed to evaluate the associations of pazopanib response with NLR, PLR, and LMR among patients with advanced soft-tissue sarcoma. METHODS: Data regarding NLR, PLR, and LMR were obtained for 25 patients who received pazopanib for soft-tissue sarcoma. The patients were categorized according to their values for NLR (≥3.8 vs. <3.8), PLR (≥230 vs. <230), and LMR (≥2.4 vs. <2.4), and we evaluated the associations of these markers with progression-free survival and overall survival using Kaplan-Meier curves and Cox proportional models. RESULTS: No significant differences in progression-free survival or overall survival were observed based on the pre-treatment NLR, PLR, and LMR values. However, decreased NLR values after treatment using pazopanib were independently associated with significantly prolonged progression-free survival (hazard ratio: 0.07, p = 0.001) and overall survival (hazard ratio: 0.17, p = 0.0006). CONCLUSIONS: Decreased NLR values after treatment using pazopanib may predict high efficacy and favorable outcomes among patients with advanced soft-tissue sarcoma.
BACKGROUND:Pazopanib is a multi-tyrosine kinase inhibitor that is used to treat advanced soft-tissue sarcoma, and its efficacy has been confirmed in several clinical trials, although no clinically useful biomarkers have been identified. In other cancers, the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the lymphocyte-to-monocyte ratio (LMR) are associated with chemotherapy response and prognosis. Therefore, we aimed to evaluate the associations of pazopanib response with NLR, PLR, and LMR among patients with advanced soft-tissue sarcoma. METHODS: Data regarding NLR, PLR, and LMR were obtained for 25 patients who received pazopanib for soft-tissue sarcoma. The patients were categorized according to their values for NLR (≥3.8 vs. <3.8), PLR (≥230 vs. <230), and LMR (≥2.4 vs. <2.4), and we evaluated the associations of these markers with progression-free survival and overall survival using Kaplan-Meier curves and Cox proportional models. RESULTS: No significant differences in progression-free survival or overall survival were observed based on the pre-treatment NLR, PLR, and LMR values. However, decreased NLR values after treatment using pazopanib were independently associated with significantly prolonged progression-free survival (hazard ratio: 0.07, p = 0.001) and overall survival (hazard ratio: 0.17, p = 0.0006). CONCLUSIONS: Decreased NLR values after treatment using pazopanib may predict high efficacy and favorable outcomes among patients with advanced soft-tissue sarcoma.
Authors: Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger Journal: Lancet Date: 2012-05-16 Impact factor: 79.321
Authors: Patrick Schöffski; Sant Chawla; Robert G Maki; Antoine Italiano; Hans Gelderblom; Edwin Choy; Giovanni Grignani; Veridiana Camargo; Sebastian Bauer; Sun Young Rha; Jean-Yves Blay; Peter Hohenberger; David D'Adamo; Matthew Guo; Bartosz Chmielowski; Axel Le Cesne; George D Demetri; Shreyaskumar R Patel Journal: Lancet Date: 2016-02-10 Impact factor: 79.321
Authors: Dario Callegaro; Rosalba Miceli; Sylvie Bonvalot; Peter Ferguson; Dirk C Strauss; Antonin Levy; Anthony Griffin; Andrew J Hayes; Silvia Stacchiotti; Cecile Le Pechoux; Myles J Smith; Marco Fiore; Angelo P Dei Tos; Henry G Smith; Luigi Mariani; Jay S Wunder; Raphael E Pollock; Paolo G Casali; Alessandro Gronchi Journal: Lancet Oncol Date: 2016-04-05 Impact factor: 41.316
Authors: George D Demetri; Sant P Chawla; Margaret von Mehren; Paul Ritch; Laurence H Baker; Jean Y Blay; Kenneth R Hande; Mary L Keohan; Brian L Samuels; Scott Schuetze; Claudia Lebedinsky; Yusri A Elsayed; Miguel A Izquierdo; Javier Gómez; Youn C Park; Axel Le Cesne Journal: J Clin Oncol Date: 2009-08-03 Impact factor: 44.544
Authors: Sumanta Kumar Pal; Dewan Md Sakib Hossain; Qifang Zhang; Paul Henry Frankel; Jeremy O Jones; Courtney Carmichael; Christopher Ruel; Clayton Lau; Marcin Kortylewski Journal: J Urol Date: 2014-10-05 Impact factor: 7.450
Authors: Cem Mirili; Semra Paydaş; Isa B Guney; Ali Ogul; Serkan Gokcay; Mahmut Buyuksimsek; Abdullah E Yetisir; Bilgin Karaalioglu; Mert Tohumcuoglu; Gulsah Seydaoglu Journal: Cancer Manag Res Date: 2019-04-23 Impact factor: 3.989
Authors: Sang Kyum Kim; Jee Hung Kim; Seung Hyun Kim; Young Han Lee; Jung Woo Han; Wooyeol Baek; Ha Young Woo; Min Kyung Jeon; Hyo Song Kim Journal: BMC Cancer Date: 2021-03-31 Impact factor: 4.430
Authors: Samuel Hidalgo-Ríos; Jaime Carrillo-García; David S Moura; Silvia Stacchiotti; Antonio López-Pousa; Andrés Redondo; Antoine Italiano; Antonio Gutiérrez; Giovanni Grignani; Nadia Hindi; José-Antonio López-Guerrero; Xavier García Del Muro; Javier Martínez Trufero; Emanuela Palmerini; Ana Sebio García; Daniel Bernabeu; Axel Le Cesne; Paolo Giovanni Casali; Jean-Yves Blay; Josefina Cruz Jurado; Javier Martin-Broto Journal: Cancers (Basel) Date: 2022-08-29 Impact factor: 6.575